Sponsor Dossier
Sanofi-Aventis
Sponsor Dossier for Sanofi-Aventis. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACT-HIB
- Brand: ADACEL
- Brand: ADENOCOR
- Brand: ADENOSCAN
- Brand: ALDURAZYME
- Brand: ALPROLIX
- Brand: ALTUVIIIO
- Brand: AMDARONE
- Device (sponsor): Medication transfer set
- Device (sponsor): Specimen receptacle IVDs
- Device (sponsor): Medication transfer set
- Device (sponsor): Basic insulin pen, replaceable-cartridge
- Device (sponsor): Basic insulin pen, replaceable-cartridge
- Device (sponsor): SYNVISC-ONE (Hylan G-F 20) - Synovial fluid supplementation substance
- Device (sponsor): SYNVISC - Synovial fluid supplementation substance
- Device (sponsor): Dispenser, medication, liquid
About
Sanofi-Aventis is an Australian Private Company with ABN 31008558807, registered in New South Wales and currently active.
Portfolio
Sanofi-Aventis has 100 brands on the ARTG, of which 94 are indexable and 93 carry a Product Information document. 43 brands are PBS-listed, 24 have a PBAC outcome on record, and 21 have an AusPAR on record. Notable brands include ACT-HIB, ADACEL, ADENOCOR, ADENOSCAN, ALDURAZYME, ALPROLIX, ALTUVIIIO, AMDARONE, APIDRA, APX-CLOPIDOGREL/ASPIRIN, APX-PARACETAMOL/CODEINE, ARAVA.
Therapeutic focus
— Cardiology: 23 brands — Infectious Disease: 20 brands — Pain Management: 10 brands — Neurology: 9 brands — Rare Disease: 8 brands — Endocrinology: 6 brands — Oncology: 6 brands — Haematology: 5 brands — Immunology: 4 brands — Psychiatry: 3 brands — Musculoskeletal: 2 brands — Renal: 2 brands — Other: 1 brand — Reproductive Health: 1 brand
PBS footprint
43 brands are PBS-listed, with the latest PBS schedule date 2026-11-01.
Regulatory activity
The latest PBAC outcome is 2026-09-01, across 24 brands with a PBAC outcome on record. The latest AusPAR is 2026-09-29, across 21 brands with an AusPAR on record.